Local drug delivery system for the treatment of osteomyelitis: In vitro evaluation

Drug Development and Industrial Pharmacy

Volumn 37, Issue 5, 2011, Pages 538-546

  Soundrapandian, Chidambaram ^a,b   Basu, Debabrata ^a   Sa, Biswanath ^a   Datta, Someswar ^a  

^a CSIR CENTRAL GLASS AND CERAMIC RESEARCH INSTITUTE   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

bioceramic; bone implant; bone infection; ceramic implants; chitosan; composite; Drug release; fluconazole; gatifloxacin; skeletal drug delivery

Indexed keywords

FLUCONAZOLE; GATIFLOXACIN; GLASS; MERCURY; SCAFFOLD PROTEIN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; FOURIER TRANSFORMATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; OSTEOMYELITIS; X RAY DIFFRACTION;

ANTI-INFECTIVE AGENTS, LOCAL; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUCONAZOLE; FLUOROQUINOLONES; GLASS; KINETICS; MATERIALS TESTING; OSTEOMYELITIS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE SCAFFOLDS; X-RAY DIFFRACTION;

EID: 79953773206     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.528427     Document Type: Article

References (38)

1. Agathopoulos S, Tulyaganov DU, Ventura JMG, Kannan S, Saranti A, Karakassides MA, Ferreira JMF. (2006). Structural analysis and devitrification of glasses based on the CaO-MgO-SiO2 system with B2O3, Na2O, CaF2 and P2O5 additives. J Non-Cryst Solids, 352:322-328.
2. Aina V, Perardi A, Bergandi L, Malavasi G, Menabue L, Morterra C et al. (2007). Cytotoxicity of zinc-containing bioactive glasses in contact with human osteoblasts. Chem Biol Interact, 167:207-218. (Pubitemid 46529405)
3. Andrade AL, Souza DM, Vasconcellos WA, Ferreira RV, Domingues RZ. (2009). Tetracycline and/or hydrocortisone incorporation and release by bioactive glasses compounds. J NonCryst Solids, 355:811-816.
4. Balamurugan A, Balossier G, Michel J, Kannan S, Benhayoune H, Rebelo AH et al. (2007). Sol gel derived SiO(2)-CaO-MgO-P(2) O(5) bioglass system-preparation and in vitro characterization. J Biomed Mater Res Part B Appl Biomater, 83:546-553. (Pubitemid 350005027)
5. Baldrick P. (2010). The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol, 56:290-299.
6. Bang H-G, Kim S-J, Park S-Y. (2008). Biocompatibility and the physical properties of bio-glass ceramics in the Na2O-CaO-SiO2-P2O5 system with CaF2 and MgF2 additives. J Ceram Process Res, 9:588-590.
7. Cekic ND, Milic JR, Savic SD, Savic MM, Jovic Z, Daniels R. (2009). Influence of the preparation procedure and chitosan type on physicochemical properties and release behavior of alginatechitosan microparticles. Drug Dev Ind Pharm, 35:1092-1102.
8. Chevalier E, Viana M, Cazalbou S, Chulia D. (2009). Comparison of low-shear and high-shear granulation processes: effect on implantable calcium phosphate granule properties. Drug Dev Ind Pharm, 35:1255-1263.
9. Czarnobaj K. (2008). Preparation and characterization of silica xerogels as carriers for drugs. Drug Deliv, 15:485-492.
10. El-Ghannam A, Ahmed K, Omran M. (2005). Nanoporous delivery system to treat osteomyelitis and regenerate bone: gentamicin release kinetics and bactericidal effect. J Biomed Mater Res Part B Appl Biomater, 73:277-284. (Pubitemid 40628991)
11. El-Kamel AH, Baddour MM. (2007). Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. Drug Deliv, 14:349-356. (Pubitemid 47265817)
12. Gu C, Zheng R, Yang Z, Wen A, Wu H, Zhang H et al. (2009). Novel glycidyl methacrylated dextran/gelatin nanoparticles loaded with basic fibroblast growth factor: formulation and characteristics. Drug Dev Ind Pharm, 35:1419-1429.
13. Hing KA. (2005). Bioceramic bone graft substitutes: influence of porosity and chemistry. Int J Appl Ceram Technol, 2:184-199. (Pubitemid 40951789)
14. Hughes SP, Anderson FM. (1985). Penetration of antibiotics into bone. J Antimicrob Chemother, 15:517-519. (Pubitemid 15093190)
15. Itokazu M, Ohno T, Tanemori T, Wada E, Kato N, Watanabe K. (1997). Antibiotic-loaded hydroxyapatite blocks in the treatment of experimental osteomyelitis in rats. J Med Microbiol, 46:779-783. (Pubitemid 27376780)
16. Kählig H, Hasanovic A, Biruss B, Höller S, Grim J, Valenta C. (2009). Chitosan-glycolic acid: a possible matrix for progesterone delivery into skin. Drug Dev Ind Pharm, 35:997-1002.
17. Kong M, Chen XG, Liu CS, Liu CG, Meng XH, Yu le J. (2008). Antibacterial mechanism of chitosan microspheres in a solid dispersing system against E. coli. Colloids Surf B Biointerfaces, 65:197-202.
18. Kontonasaki E, Zorba T, Papadopoulou L, Pavlidou E, Chatzistavrou X, Paraskevopoulos K, Koidis P. (2002). Hydroxy carbonate apatite formation on particulate bioglass in vitro as a function of time. Cryst Res Technol, 37:1165-1171.
19. Kundu B, Soundrapandian C, Nandi SK, Mukherjee P, Dandapat N, Roy S et al. (2010). Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial. Pharm Res, 27:1659-1676.
20. Lin A, Chen J, Liu Y, Deng S, Wu Z, Huang Y, Ping Q. (2009). Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm, 35:1348-1355.
21. Melville AJ, Rodrä-guez-Lorenzo LM, Forsythe JS. (2008). Effects of calcination temperature on the drug delivery behaviour of Ibuprofen from hydroxyapatite powders. J Mater Sci Mater Med, 19:1187-1195. (Pubitemid 351328129)
22. Nandi SK, Kundu B, Mukherjee P, Mandal TK, Datta S, De DK, Basu D. (2009). In vitro and in vivo release of cefuroxime axetil from bioactive glass as an implantable delivery system in experimental osteomyelitis. Ceram Int, 35:3207-3216.
23. NCCLS. (2002). Performance standards for antimicrobial susceptibility testing. NCCLS, Wayne, Pa.
24. Ouédraogo M, Semdé R, Somé IT, Traoré- Ouédraogo R, Guissou IP, Henschel V et al. (2008). Monoolein-water liquid crystalline gels of gentamicin as bioresorbable implants for the local treatment of chronic osteomyelitis: in vitro characterization. Drug Dev Ind Pharm, 34:753-760. (Pubitemid 351962347)
25. Park Y, Kim MH, Park SC, Cheong H, Jang MK, Nah JW et al. (2008). Investigation of the antifungal activity and mechanism of action of LMWS-chitosan. J Microbiol Biotechnol, 18:1729-1734.
26. Radev L, Hristov V, Samuneva B, Ivanova D. (2009). Organic/inorganic bioactive materials Part II: in vitro bioactivity of collagen-calcium phosphate silicate/wollastonite hybrids. Cent Eur J Chem, 7:711-720.
27. Rossi S, Marciello M, Sandri G, Bonferoni MC, Ferrari F, Caramella C. (2008). Chitosan ascorbate: a chitosan salt with improved penetration enhancement properties. Pharm Dev Technol, 13:513-521.
28. Schierholz JM, Steinhauser H, Rump AF, Berkels R, Pulverer G. (1997). Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features. Biomaterials, 18:839-844. (Pubitemid 27239146)
29. Seeley Z, Bandyopadhyay A, Bose S. (2008). Tricalcium phosphate based resorbable ceramics: Influence of NaF and CaO addition. Mat Sci Eng C, 28:11-17. (Pubitemid 350297876)
30. Shirtliff ME, Calhoun JH, Mader JT. (2002). Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits. Antimicrob Agents Chemother, 46:231-233. (Pubitemid 34031632)
31. Soundrapandian C, Datta S, Sa B. (2007). Drug-eluting implants for osteomyelitis. Crit Rev Ther Drug Carrier Syst, 24:493-545. (Pubitemid 351234918)
32. Soundrapandian C, Sa B, Datta S. (2009). Organic-inorganic composites for bone drug delivery. AAPS Pharmscitech, 10:1158-1171.
33. Tian Y, Li L, Gao X, Deng J, Stephens D, Robinson D et al. (2002). The effect of storage temperatures on the in vitro properties of a polyanhydride implant containing gentamicin. Drug Dev Ind Pharm, 28:897-903.
34. Ubaidulla U, Khar RK, Ahmad FJ, Tripathi P. (2009). Optimization of chitosan succinate and chitosan phthalate microspheres for oral delivery of insulin using response surface methodology. Pharm Dev Technol, 14:96-105.
35. Wachol-Drewek Z, Pfeiffer M, Scholl E. (1996). Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin. Biomaterials, 17:1733-1738. (Pubitemid 26278982)
36. Xia W, Chang J. (2006). Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system. J Control Release, 110:522-530. (Pubitemid 43163442)
37. Zhao L, Yan X, Zhou X, Zhou L, Wang H, Tang J, Yu C. (2008). Mesoporous bioactive glasses for controlled drug release. Micropor Mesopor Mat, 109:210-215. (Pubitemid 350297104)
38. Zhu Y, Kaskel S. (2009). Comparison of the in vitro bioactivity and drug release property of mesoporous bioactive glasses (MBGs) and bioactive glasses (BGs) scaffolds. Micropor Mesopor Mat, 118:176-182.